文献速递运动医学关节外科

关节镜骨髓刺激术是否应用于距骨继发性骨软骨损伤的治疗?一项系统综述

Should Arthroscopic Bone Marrow Stimulation Be Used in the Management of Secondary Osteochondral Lesions of the Talus? A Systematic Review.
PubMed 文献 · Clin Orthop Relat Res · 2022-02-07

该系统综述纳入12篇文章共446例患者,其中111例距骨继发性骨软骨损伤患者接受关节镜骨髓刺激术;患者报告结局改善不一致且常较小,约三分之一患者接受翻修手术;作者认为除非能细化选择标准,否则不能推荐该术式。

要点

  • 距骨继发性骨软骨损伤行关节镜骨髓刺激术后患者报告结局改善不一致且常较小。
  • 报告该终点的7项研究中34%(26/77)患者接受了翻修手术,未报告围手术期并发症。
  • 一项研究发现病灶大小与AOFAS和VAS评分呈负相关,其余研究未报告相关因素。

核心结论

  • 关节镜骨髓刺激术治疗距骨继发性骨软骨损伤的患者报告结局改善不一致且常较小,约三分之一患者接受翻修手术。
  • 报告结局可能代表最佳情况,被低级别研究设计和已知使治疗效果显得更大的主要偏倚来源所夸大。
  • 作者认为除非能细化选择标准以有效识别可获得实质性临床获益的患者,否则不能推荐在此类患者中使用关节镜骨髓刺激术。

研究设计与样本

  • 遵循PRISMA指南的系统综述,检索Embase、EmCare、PubMed、CINAHL和Scopus数据库(最后检索日期2021年6月23日)。
  • 由两名评价者独立进行两阶段标题/摘要和全文筛选,纳入评估关节镜骨髓刺激术治疗距骨继发性骨软骨损伤的随机对照试验、队列研究和观察性研究。
  • 排除病例报告、综述文章、评论、摘要和致编辑的信;共纳入12篇文章(10项病例系列和2项回顾性比较研究),涉及446例患者。
  • 其中111例距骨继发性骨软骨损伤患者接受关节镜骨髓刺激术,平均年龄33岁(范围20至49岁)。
  • 采用MINORS标准评估方法学质量:10项非比较病例系列最高分为16分中的10分,中位(范围)评分为7.5(4至10);2项比较研究分别得24分中的22分和19分。

主要发现

  • 研究报告的患者报告结局指标(如AOFAS评分)差异很大,关于患者是否改善或改善程度的报告不一致;部分效应量显示改善接近或低于最小临床重要差异(MCID)。
  • 纳入研究均未报告围手术期并发症,但报告该终点的7项研究中34%(26/77)患者接受了翻修手术。
  • 一项研究发现病灶大小与AOFAS和VAS评分呈负相关;无其他研究报告与患者报告结局评分相关的因素,且大多数研究样本量远不足以探索此类关系。

临床怎么用

  • 作者认为除非能细化选择标准以有效识别可获得实质性临床获益的患者,否则不能推荐对距骨继发性骨软骨损伤患者使用关节镜骨髓刺激术。

局限性

  • 纳入研究样本量小且异质性大,主要发现存在差异。
  • 大多数研究样本量远不足以探索与患者报告结局评分相关的因素。
  • 报告结局可能代表最佳情况,被低级别研究设计和已知使治疗效果显得更大的主要偏倚来源所夸大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Osteochondral lesions of the talus are common, particularly after trauma. Arthroscopic bone marrow stimulation has emerged as the first-choice surgical treatment for small primary lesions less than 100 mm2. Individual studies on the topic are small and heterogeneous, and they have differed in their main findings; for this reason, systematically reviewing the available evidence seems important. QUESTIONS/PURPOSES: In this systematic review, we asked: (1) What patient-reported outcomes and pain scores have been observed after arthroscopic bone marrow stimulation for secondary osteochondral lesions of the talus? (2) What complications were reported? (3) What demographic and clinical factors were reported to be associated with better patient-reported outcome scores? METHODS: We performed a systematic review according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines using Embase, EmCare, PubMed, CINAHL, and Scopus (databases last searched June 23, 2021). A two-stage title/abstract and full-text screening process was performed independently by two reviewers. Randomized control trials, cohort studies, and observational studies published in English that evaluated the outcome of arthroscopic bone marrow stimulation for secondary osteochondral lesions of the talus were included. Case reports, review articles, commentaries, abstracts, and letters to the editor were excluded. A total of 12 articles (10 case series and two retrospective comparative studies) involving 446 patients were included. Of these, 111 patients with a mean age of 33 years (range 20 to 49) received arthroscopic bone marrow stimulation for a secondary osteochondral lesion of the talus. The Methodological Index for Non-randomized Studies (MINORS) criteria were used to assess the methodologic quality of included studies. The MINORS is a numerical score ranging from 0 to 16 for studies with no comparison group and 0 to 24 for comparative studies, with higher quality studies receiving higher scores. Of the 10 noncomparative case series, the highest score was 10 of 16, with a median (range) score of 7.5 (4 to 10), while the two comparative studies scored 22 of 24 and 19 of 24, respectively. RESULTS: Studies varied widely in terms of patient-reported outcome measures such as the American Orthopaedic Foot and Ankle Society score (AOFAS), with inconsistent reporting across studies regarding whether or how much patients improved; there was variation in some effect sizes with regard to improvement seeming close to or below the minimum clinically important difference (MCID). Although no perioperative complications were reported in any included studies, 34% (26 of 77, in seven studies that reported on this endpoint) of patients who underwent a revision procedure. One study found a negative association between lesion size and AOFAS and VAS score. No other studies reported on factors associated with patient-reported outcome scores, and most studies were far too small to explore relationships of this sort. CONCLUSION: We found that arthroscopic bone marrow stimulation for secondary osteochondral lesions of the talus yielded inconsistent and often small improvements in patient-reported outcomes, with approximately one in three patients undergoing a revision procedure. Reported outcomes likely represent a best-case scenario, inflated by low-level study designs and major sources of bias that are known to make treatment effects seem larger than they are. Therefore, the use of arthroscopic bone marrow stimulation in such patients cannot be recommended, unless we are able to refine selection criteria to effectively identify patients who show a substantial clinical benefit. LEVEL OF EVIDENCE: Level IV, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Arshad Z, Aslam A, Iqbal AM, et al. Should Arthroscopic Bone Marrow Stimulation Be Used in the Management of Secondary Osteochondral Lesions of the Talus? A Systematic Review. Clin Orthop Relat Res. 2022. PMID: 35130190. doi:10.1097/CORR.0000000000002134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。